United Services Automobile Association lessened its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 15.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,908 shares of the life sciences company’s stock after selling 1,941 shares during the period. United Services Automobile Association’s holdings in Integra Lifesciences were worth $492,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund grew its holdings in shares of Integra Lifesciences by 4,410.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 1,226,245 shares in the last quarter. Capital World Investors grew its holdings in shares of Integra Lifesciences by 438.9% in the 3rd quarter. Capital World Investors now owns 1,137,015 shares of the life sciences company’s stock valued at $74,895,000 after acquiring an additional 926,015 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its holdings in shares of Integra Lifesciences by 138.5% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 880,167 shares of the life sciences company’s stock valued at $39,695,000 after acquiring an additional 511,085 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of Integra Lifesciences by 4.3% in the 3rd quarter. Capital Research Global Investors now owns 10,186,218 shares of the life sciences company’s stock valued at $670,966,000 after acquiring an additional 423,324 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Integra Lifesciences by 549.3% in the 3rd quarter. Renaissance Technologies LLC now owns 358,160 shares of the life sciences company’s stock valued at $23,592,000 after acquiring an additional 303,000 shares in the last quarter. Hedge funds and other institutional investors own 83.91% of the company’s stock.
Several equities analysts have recently weighed in on IART shares. SunTrust Banks started coverage on Integra Lifesciences in a report on Thursday, January 3rd. They issued a “buy” rating and a $56.00 price objective for the company. Cantor Fitzgerald set a $54.00 price target on Integra Lifesciences and gave the stock a “hold” rating in a report on Tuesday, January 8th. Morgan Stanley set a $57.00 price target on Integra Lifesciences and gave the stock a “hold” rating in a report on Friday, February 22nd. JMP Securities reiterated a “buy” rating and set a $62.00 price target on shares of Integra Lifesciences in a report on Wednesday, February 27th. Finally, BidaskClub cut Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, December 27th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $59.75.
IART stock traded down $1.68 during mid-day trading on Wednesday, hitting $51.34. 931,111 shares of the company were exchanged, compared to its average volume of 498,182. The company has a quick ratio of 1.88, a current ratio of 2.95 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $4.42 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.51 and a beta of 0.96. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $67.50.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. The company had revenue of $359.69 million during the quarter, compared to the consensus estimate of $361.12 million. During the same period in the previous year, the business earned $0.58 earnings per share. The firm’s quarterly revenue was up .7% on a year-over-year basis. As a group, research analysts expect that Integra Lifesciences Holdings Corp will post 2.68 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Integra Lifesciences Holdings Corp (IART) Holdings Cut by United Services Automobile Association” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/united-services-automobile-association-trims-stake-in-integra-lifesciences-holdings-corp-iart.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: What is Depreciation?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.